{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.98","upperLimit":"12.00","value":"6.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.00","upperLimit":"8.00","value":"4.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Treatment - week 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"}],"paramType":"MEDIAN","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)","title":"Time to Reach Cmax (Tmax) of Alectinib","type":"SECONDARY","unitOfMeasure":"hours"}